Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0195


HER2 status-based selection of gastric cancer patients for trastuzumab treatment.

Maurizio Degiuli, MD.

Affiliation: Dr. Maurizio Degiuli, Ospedale San Giovanni Battista, di Torino-Presidio SGAS-Sc Chirurgia Generale, 10-Turin, Italy.


Since there is no abstract available we provide the first paragraph

Treating patients with breast cancer or gastric cancer with amplification of HER2 gene or HER2 protein overexpression with the anti-HER2 monoclonal antibody trastuzumab has been characterized as the triumph of translational medicine. Indeed, among targeted drugs that are increasingly approved by the FDA, trastuzumab is the only signal transduction inhibitor that is widely used in the adjuvant setting for the treatment of early-stage breast cancer. All the other targeted drugs have been approved only for administration in the metastatic setting of various cancer types. Despite approval, only a recurrence-free survival but not overall survival benefit with trastuzumab was shown in a recent phase 3 randomized trial with the longer follow-up as compared with shorter follow-up or earlier studies. Here, I discuss the advantages but also the limitations of trastuzumab in the treatment of gastric cancer.

(Citation: Gastric & Breast Cancer 2011; 10(4) 244-246)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 9 September 2011